Changeflow GovPing Pharma & Drug Safety ASKGENE Pharma Granted Patent for Masked Cytokines
Routine Rule Added Final

ASKGENE Pharma Granted Patent for Masked Cytokines

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent No. US12600762B2 to ASKGENE PHARMA, INC. on April 14, 2026. The patent covers masked cytokines (prodrugs) and methods of use for stimulating the immune system, treating cancer, autoimmune diseases, or infectious diseases. The patent contains 19 claims and was filed on January 11, 2021 under Application No. 17787741.

What changed

USPTO granted Patent No. US12600762B2 to ASKGENE PHARMA, INC. for masked cytokine prodrug compositions and associated methods of use. The patent covers prodrug formulations for immune stimulation and therapeutic applications including cancer, autoimmune disease, and infectious disease treatment. The filing date was January 11, 2021, with 19 claims allowed.

Pharmaceutical companies developing cytokine-based therapeutics should monitor this patent for freedom-to-operate implications. The patent may cover competing masked cytokine approaches in the immunooncology and autoimmune treatment spaces. Inventors listed include Yuefeng Lu, Chunxiao Yu, Jian-Feng Lu, and Liqin Liu, with CPC classifications spanning multiple cytokine subcategories.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Masked cytokines and methods of use thereof

Grant US12600762B2 Kind: B2 Apr 14, 2026

Assignee

ASKGENE PHARMA, INC.

Inventors

Yuefeng Lu, Chunxiao Yu, Jian-Feng Lu, Liqin Liu

Abstract

Provided herein are prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer, autoimmune or an infectious disease.

CPC Classifications

C07K 14/7155 C07K 14/54 C07K 14/5418 C07K 14/5433 C07K 14/55

Filing Date

2021-01-11

Application No.

17787741

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600762B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting IP licensing Biologic drug development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!